Table 1 Study parameters in LVSI-negative and LVSI-positive groups
Parameter | LVSI-negative | LVSI-positive | p-value |
|---|---|---|---|
Age (years) | 54.46 ± 9.57 | 54.77 ± 9.88 | 0.782 |
Parity | 3.55 ± 2.67 | 3.29 ± 2.52 | 0.402 |
Menopause status | 203 (64.4%) | 69 (69%) | 0.620 |
Chief complaint at diagnosis | |||
 Post-menopausal bleeding | 201 (64.2%) | 68 (68%) | 0.444 |
 Menometrorrhagia | 106 (33.9%) | 31 (31%) | 0.197 |
 Past medical history | 155 (63.5%) | 36 (62.1%) | 0.836 |
Comorbidity | |||
 Diabetes mellitus | 85 (37.6%) | 46 (59.7%) | 0.025 |
 Hypertension | 47 (20.8%) | 8 (10.4%) | |
 Hypothyroidism | 9 (4%) | 5 (6.5%) | |
 Hypertension and diabetes mellitus | 47 (20.8%) | 12 (15.6%) | |
 Diabetes mellitus and hypothyroidism | 7 (3.1%) | 1 (1.3%) | |
 Hypertension and hypothyroidism | 9 (4%) | 1 (1.3%) | |
 Diabetes mellitus, hypertension and hypothyroidism | 7 (3.1%) | 0 (0%) | |
 Tumor size (cm) | 3.21 ± 1.81 | 3.67 ± 1.95 | 0.040 |
D&C pathology | |||
 Low-grade endometrioid carcinoma | 261 (84.7%) | 81 (81%) | 0.329 |
 Endometrioid carcinoma/hyperplasia with atypia | 34 (11%) | 9 (9%) | |
 Well-differentiated endometrioid carcinoma on polyp | 4 (1.3%) | 3 (3%) | |
Final pathology | |||
 Endometrioid carcinoma | 303 (96.2%) | 96 (96%) | 0.524 |
 Synchronous ovarian/uterine endometrioid carcinoma | 1 (0.3%) | 0 (0%) | |
 Endometrioid carcinoma on polyp | 3 (1%) | 2 (2%) | |
Myometrial invasion | |||
  < 50% | 222 (70.5%) | 53 (53%) | 0.000 |
  > 50% | 56 (17.8%) | 45 (45%) | |
 Absence of myometrial invasion | 36 (11.4%) | 1 (1%) | |
 Lower segment involvement | 46 (14.6%) | 23 (23%) | 0.049 |
Adjuvant therapy | |||
 No adjuvant therapy | 170 (54.7%) | 30 (30%) | 0.000 |
 Brachytherapy | 98 (31.5%) | 31 (31%) | |
 Brachytherapy and EBRTa | 38 (12.2%) | 34 (34%) | |
Stage | |||
 IA | 260 (82.5%) | 56 (56%) | 0.000 |
 IB | 55 (17.5%) | 44 (44%) | |
Grade | |||
 I | 213 (67.6%) | 56 (56%) | 0.034 |
 II | 102 (32.4%) | 44 (44%) | |
Lymphadenectomy | |||
 No lymphadenectomy | 121 (38.5%) | 40 (40%) | 0.954 |
 Only pelvic lymphadenectomy | 158 (50.3%) | 49 (49%) | |
 Sampling(suspicious lymph nodes) | 19 (6.1%) | 5 (5%) | |
 Complete (pelvic and para-aortic lymphadenectomy) | 16 (5.1%) | 6 (6%) | |
 Recurrence | 28 (8.9%) | 25 (25%) | 0.000 |
Recurrence site | |||
 Pelvis | 9 (34.6%) | 10 (40%) | 0.847 |
 Abdomen | 8 (30.8%) | 6 (24%) | |
 Distant | 7 (26.9%) | 8 (32%) | |
 Pelvis and distant | 1 (3.8%) | 1 (4%) | |
 Cervix | 1 (3.8%) | 0 (0%) | |
 Recurrence time (months) | 33.65 ± 21.02 | 23.04 ± 14.88 | 0.043 |
 Overall 3-year survival | 311 (98.7%) | 92 (92%) | 0.000 |
 Overall 5-year survival | 290 (92.1%) | 79 (79%) | 0.000 |